Patients Before Middlemen Act This bill establishes certain standards and reporting requirements for prescription drug plan (PDP) sponsors, pharmacy benefit managers (PBMs), and pharmacies under the Medicare prescription drug benefit and Medicare Advantage. Specifically, the Centers for Medicare & Medicaid Services (CMS) must develop reasonable and relevant standards for contracts between PDP sponsors and pharmacies. The CMS must seek input from interested stakeholders when developing these standards. PDP sponsors are subject to civil penalties for violating these standards; PBMs must reimburse PDP sponsors for civil penalties that result from their responsibilities. The bill also requires the CMS to report periodically on essential retail pharmacies (i.e., pharmacies that serve as the only pharmacy within a certain radius) with respect to costs, contracts, and other specified information, particularly in relation to other types of pharmacies. Additionally, PBMs may not receive any income other than flat, bona fide service fees. PBMs must turn over any excess amounts they receive to PDP sponsors; PDP sponsors must turn over these amounts to the CMS. In addition, PBMs must report to PDP sponsors and to the CMS an itemized list of prescription drugs that were dispensed during the previous year and related data about costs, claims, affiliated pharmacies, and other specified information. PDP sponsors may audit PBMs to ensure compliance with these requirements and must annually certify their compliance; PBMs are responsible for any associated civil penalties for violations. The bill's changes generally apply beginning in 2028.
Read twice and referred to the Committee on Finance.
Bill introduced
Lobbying filed by AMERICA'S HEALTH INSURANCE PLANS INC (AHIP)
Lobbying filed by PFIZER INC.
Lobbying filed by PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Lobbying filed by CVS HEALTH (AND SUBSIDIARIES)
Read twice and referred to the Committee on Finance.
| Registrant | Client | Amount | Filed | Period | Issues |
|---|---|---|---|---|---|
| AMERICA'S HEALTH INSURANCE PLANS, INC. (AHIP) | AMERICA'S HEALTH INSURANCE PLANS INC (AHIP) | $4.8M | Apr 21, 2025 | 2025Q1 | HCRMMMINS |
| PFIZER INC. | PFIZER INC. | $4.2M | Apr 21, 2025 | 2025Q1 | BUDHCRMMM |
| PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION |
The lobbying table lists Senate LDA quarterly reports (LD-2) that cite this bill by number and cover a quarter of the 119th Congress. An LD-2 names a bill as “H.R. 1234” with no Congress, so a report on another Congress, which can only concern a different bill with the same number, is left out, even when it was filed after this Congress began. The amount is what the registrant reported for the whole filing, across every issue on it, not spending on this bill. Official actions and the bill summary come from Congress.gov, and votes from the roll-call record. This page no longer pairs the bill with members' stock trades: matching lobbying clients to traded companies by name, and trades to a bill by date, is not something the records establish.
Lobbying filed by AMERICA'S HEALTH INSURANCE PLANS INC (AHIP)
| PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION |
| $4.1M |
| Apr 21, 2025 |
| 2025Q1 |
MMMHCRPHA |
| AMERICA'S HEALTH INSURANCE PLANS, INC. (AHIP) | AMERICA'S HEALTH INSURANCE PLANS INC (AHIP) | $4.0M | Jul 21, 2025 | 2025Q2 | HCRMMMINS |
| CVS HEALTH (AND SUBSIDIARIES) | CVS HEALTH (AND SUBSIDIARIES) | $3.5M | Apr 21, 2025 | 2025Q1 | PHATAXMMM |
| PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | $3.4M | Jul 21, 2025 | 2025Q2 | MMMHCRPHA |
| ELEVANCE HEALTH, INC. | ELEVANCE HEALTH, INC. | $2.5M | Apr 21, 2025 | 2025Q1 | HCRINSMMM |
| CVS HEALTH (AND SUBSIDIARIES) | CVS HEALTH (AND SUBSIDIARIES) | $1.8M | Jul 21, 2025 | 2025Q2 | PHATAXMMM |
| GSK (FKA GLAXOSMITHKLINE INC.) | GSK (FKA GLAXOSMITHKLINE INC.) | $1.5M | Jul 21, 2025 | 2025Q2 | BUDCPTHCR |
| ELEVANCE HEALTH, INC. | ELEVANCE HEALTH, INC. | $1.4M | Jul 21, 2025 | 2025Q2 | HCRINSMMM |
| EMD SERONO, INC. | EMD SERONO INC | $910.0K | Jul 21, 2025 | 2025Q2 | HCRMMMPHA |
| EMD SERONO, INC. | EMD SERONO INC | $900.0K | Apr 21, 2025 | 2025Q1 | SCITRDHCR |
| GSK (FKA GLAXOSMITHKLINE INC.) | GSK (FKA GLAXOSMITHKLINE INC.) | $800.0K | Apr 21, 2025 | 2025Q1 | BUDCPTHCR |
| NATIONAL ASSOCIATION OF CHAIN DRUG STORES | NATIONAL ASSOCIATION OF CHAIN DRUG STORES | $690.0K | Jul 18, 2025 | 2025Q2 | PHAMMMBUD |
| CAMBIA HEALTH SOLUTIONS | CAMBIA HEALTH SOLUTIONS | $630.0K | Jul 18, 2025 | 2025Q2 | HCRMMM |
| CAMBIA HEALTH SOLUTIONS | CAMBIA HEALTH SOLUTIONS | $620.0K | Apr 21, 2025 | 2025Q1 | HCRMMM |
| FOOD MARKETPLACE INC. | FOOD MARKETPLACE INC | $420.0K | Apr 21, 2025 | 2025Q1 | AGRCSPENV |
| NATIONAL ASSOCIATION OF CHAIN DRUG STORES | NATIONAL ASSOCIATION OF CHAIN DRUG STORES | $360.0K | Apr 18, 2025 | 2025Q1 | PHAMMMBUD |
| NATIONAL COMMUNITY PHARMACISTS ASSOCIATION | NATIONAL COMMUNITY PHARMACISTS ASSOCIATION | $350.0K | Jul 21, 2025 | 2025Q2 | ALCMMMPHA |
| NATIONAL COMMUNITY PHARMACISTS ASSOCIATION | NATIONAL COMMUNITY PHARMACISTS ASSOCIATION | $340.0K | Apr 21, 2025 | 2025Q1 | ALCMMMPHA |
| FOOD MARKETPLACE INC. | FOOD MARKETPLACE INC | $310.0K | Jul 21, 2025 | 2025Q2 | MONPHAAGR |
| AMERICAN COLLEGE OF RHEUMATOLOGY | AMERICAN COLLEGE OF RHEUMATOLOGY | $180.0K | Jul 21, 2025 | 2025Q2 | HCRBUDMMM |
| AMERICAN COLLEGE OF RHEUMATOLOGY | AMERICAN COLLEGE OF RHEUMATOLOGY | $80.0K | Apr 21, 2025 | 2025Q1 | HCRBUDMMM |
| INDEPENDENT PHARMACY COOPERATIVE | INDEPENDENT PHARMACY COOPERATIVE | $50.0K | Jul 17, 2025 | 2025Q2 | PHA |
| INDEPENDENT PHARMACY COOPERATIVE | INDEPENDENT PHARMACY COOPERATIVE | $40.0K | Apr 12, 2025 | 2025Q1 | PHA |
| WAKEFERN FOOD CORP. | WAKEFERN FOOD CORP. | Undisclosed | Jul 15, 2025 | 2025Q2 | PHALAWAGR |
| WAKEFERN FOOD CORP. | WAKEFERN FOOD CORP. | Undisclosed | Apr 14, 2025 | 2025Q1 | PHALAWAGR |